/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of.
Pancreatic Cancer Pipeline is enriched with novel therapeutic strategies, including a broad range of therapies targeting diverse biologic processes. The.
Increasing awareness about the condition, improved diagnostic techniques and a robust drug pipeline promises a better future Non-Hodgkin's Lymphoma Space.
Erdafitinib (Janssen Research and Development).
The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing.
Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a much-needed momentum.
Get in touch for a holistic view of the
The BTC market report also covers the market of Cholangiocarcinoma including (Intrahepatic and Extrahepatic), Gallbladder, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market s underlying potential, and plans strategically to tackle market risks.